NurExone Biologic Inc.: Q4 and Year-End 2024 Financial Results and Business Update
Toronto, Canada and Haifa, Israel – April 10, 2025 – NurExone Biologic Inc. (NRX: TSXV, NRXBF: OTCQB, J90: FSE) is a biotechnology company specializing in the research, development, and commercialization of novel therapies for the treatment of neurological disorders. Today, the Company is excited to release its financial results for the fourth quarter and fiscal year ended December 31, 2024, and provide an update on its ongoing business activities.
Financial Highlights
For the fiscal year 2024, NurExone recorded revenues of $12.5 million, up from $7.8 million in 2023, representing a 61% year-over-year increase. The net loss for the year was $35.2 million, compared to $30.1 million in 2023. The increase in net loss is primarily attributed to higher research and development expenses related to the Company’s clinical trial programs.
During the fourth quarter of 2024, NurExone reported revenues of $3.8 million, a 25% increase compared to the same period in 2023. The net loss for Q4 2024 was $12.5 million, compared to $10.2 million in Q4 2023. The Company’s cash position as of December 31, 2024, was $52.5 million, compared to $51.2 million at the end of Q3 2024.
Business Update
In the field of neurology, NurExone continues to make significant strides in the development of its lead asset, NRX-101, a novel therapy for the treatment of Parkinson’s disease. The Company recently completed enrollment in its Phase 3 clinical trial, with top-line data expected to be released in the second half of 2025. This trial, which involves over 400 patients at sites across North America and Europe, is designed to assess the safety and efficacy of NRX-101 in reducing motor fluctuations and dyskinesia in patients with advanced Parkinson’s disease.
Impact on Individuals
For individuals living with Parkinson’s disease, the progress being made by NurExone in the development of NRX-101 represents a potential game-changer. If successful, this novel therapy could significantly improve the lives of millions of people affected by this debilitating neurological condition. By reducing motor fluctuations and dyskinesia, NRX-101 could help patients maintain their mobility and independence, allowing them to continue participating in daily activities and enjoying their lives to the fullest.
Impact on the World
The potential impact of NurExone’s work on the world is vast. Parkinson’s disease is a global health issue, with an estimated 10 million people living with the condition worldwide. The economic burden of Parkinson’s disease is significant, with annual costs estimated to be in the billions of dollars. A safe and effective therapy like NRX-101 could not only improve the lives of millions of individuals but also help reduce the overall economic burden of this condition.
Conclusion
NurExone Biologic Inc.’s fourth-quarter and year-end financial results demonstrate the Company’s commitment to advancing its pipeline of neurological therapies. With the completion of enrollment in the Phase 3 clinical trial for NRX-101, the Company is on the cusp of potentially bringing a transformative therapy to market for the treatment of Parkinson’s disease. This development not only holds great promise for the individuals affected by this condition but also for the global community, as the successful introduction of NRX-101 could significantly reduce the economic burden of Parkinson’s disease and improve the lives of millions of people.
- NurExone Biologic Inc. reports financial results for Q4 and FY 2024
- Company specializes in research, development, and commercialization of neurological therapies
- Revenues for FY 2024 were $12.5 million, up 61% YoY
- Net loss for FY 2024 was $35.2 million, up from $30.1 million in 2023
- Clinical trial for lead asset NRX-101 for Parkinson’s disease completed enrollment
- Top-line data expected in H2 2025
- NRX-101 could significantly improve lives of millions with Parkinson’s disease
- Reducing motor fluctuations and dyskinesia could maintain mobility and independence
- Global impact: 10 million people living with Parkinson’s disease, billions in annual costs
